Last reviewed · How we verify
Placebo for CAB LA
A placebo control contains no active pharmaceutical ingredient and serves as a comparator in clinical trials to establish the efficacy of the active investigational drug.
A placebo control contains no active pharmaceutical ingredient and serves as a comparator in clinical trials to establish the efficacy of the active investigational drug. Used for Control arm in Phase 3 trial for cabotegravir long-acting (CAB LA) in HIV prevention or treatment.
At a glance
| Generic name | Placebo for CAB LA |
|---|---|
| Also known as | Placebo for long acting cabotegravir |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Placebos are inert formulations used in randomized controlled trials to provide a baseline against which the effects of an active drug can be measured. In this Phase 3 trial for CAB LA (cabotegravir long-acting), the placebo arm allows researchers to distinguish genuine drug effects from natural disease progression, spontaneous remission, or psychological effects. Placebo responses help establish the true clinical benefit of the investigational treatment.
Approved indications
- Control arm in Phase 3 trial for cabotegravir long-acting (CAB LA) in HIV prevention or treatment
Common side effects
Key clinical trials
- Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men (PHASE2, PHASE3)
- Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for CAB LA CI brief — competitive landscape report
- Placebo for CAB LA updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI